Disable all preview features

Health : Medical Research

Drugs for Neglected Diseases Initiative North America

Developing new drugs for patients suffering from the most neglected communicable diseases

three stars

82.48

40 Wall Street 24th Floor
New York, NY 10005
tel: (646) 616-8680   Web Site
EIN: 20-8774179

Board Leadership
Darin Portnoy
Chair

CEO
Rachel Cohen
Regional Executive Director

  Score
(out of 100)
Rating
Overall Score & Rating 82.48 three stars
  Financial 77.80 two stars
  Accountability & Transparency 89.00 three stars
This rating was published 02/01/2021 and includes data from FY2019, the most recent 990 received at that time.

The mission of Drugs for Neglected Diseases Initiative North America (DNDi NA) is to develop new drugs, or new formulations of existing drugs, for patients suffering from the most neglected communicable diseases. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. DNDi's primary focus has been the development of drugs for the most neglected diseases, such as human African trypanosomiasis (HAT, or sleeping sickness), visceral leishmaniasis (kala-azar), and Chagas disease, while considering engagement in R&D projects for other neglected diseases or development of diagnostics and/or vaccines to address unmet needs that others are unable or unwilling to address.

The mission of Drugs for Neglected Diseases Initiative North America (DNDi NA) is to develop new drugs, or new formulations of existing drugs, for patients suffering from the most neglected communicable diseases. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. DNDi's primary focus has been the development of drugs for the most neglected diseases, such as human African trypanosomiasis (HAT, or sleeping sickness), visceral leishmaniasis (kala-azar), and Chagas disease, while considering engagement in R&D projects for other neglected diseases or development of diagnostics and/or vaccines to address unmet needs that others are unable or unwilling to address.

Financial

two stars

77.80

Accountability & Transparency

three stars

89.00

This rating was published 02/01/2021 and includes data from FY2019, the most recent 990 received at that time.
Overall Rating Chart
  Program Expenses
(Percent of the charity's total expenses spent on the programs
and services it delivers)
77.3%
  Administrative Expenses 7.6%
  Fundraising Expenses 14.9%
  Fundraising Efficiency $0.14
  Working Capital Ratio (years) 0.10
  Program Expenses Growth 11.4%
  Liabilities to Assets 60.4%
All data for Financial Performance Metrics calculations was provided by Drugs for Neglected Diseases Initiative North America on recent 990s filed with the IRS.
All data for Financial Performance Metrics calculations was provided by Drugs for Neglected Diseases Initiative North America on recent 990s filed with the IRS.

Highly Rated

Charity Name & State Overall Score Overall Rating
Drugs for Neglected Diseases Initiative North America (NY) 82.48 three stars
Cure Alzheimer's Fund (MA) 98.23 four stars
Foundation for Angelman Syndrome Therapeutics (IL) 92.22 four stars
International Society for Infectious Diseases (MA) 87.00 three stars
Project ALS (NY) 85.57 three stars

Compare These Charities (Highly Rated)

REVENUE  
Contributions  
   Contributions, Gifts & Grants $3,793,079
   Federated Campaigns $0
   Membership Dues $0
   Fundraising Events $0
   Related Organizations $0
   Government Grants $831,995
Total Contributions $4,625,074
   Program Service Revenue $0
Total Primary Revenue $4,625,074
   Other Revenue $2,200
TOTAL REVENUE $4,627,274
   
EXPENSES  
   Program Expenses $3,337,183
   Administrative Expenses $476,548
   Fundraising Expenses $779,806
TOTAL FUNCTIONAL EXPENSES $4,593,537
   
Payments to Affiliates $0
Excess (or Deficit) for the year $33,737
   
Net Assets $534,622

Program names and associated costs are listed for the top programs as reported on the charity's most recently filed Form 990. The top programs displayed will include the largest three programs, or those programs covering at least 60% of the charity's total expenses, whichever comes first.

Program Name Amount Spent % of Program Expenses
Grants to Research and Development $2,918,686 87.5%
Raising Public Awareness $418,497 12.5%

Ratings History

Form 990 FYE Date Published Overall Score Overall Rating
CN 2.1
2019-12 02/01/2021 82.48 three stars
2018-12 11/01/2019 84.52 three stars
2017-12 02/01/2019 84.44 three stars
2016-12 02/01/2018 85.56 three stars
2015-12 02/01/2017 75.82 two stars
2015-12 12/01/2016 73.74 two stars
2014-12 06/01/2016 79.38 two stars
 
CN 2.0
2014-12 02/01/2016 70.67 two stars

The data displayed on this tab is provided by the IRS in the form of Publication 78 and the Business Master File (BMF).

EIN 20-8774179
Name in IRS Master File DRUGS FOR NEGLECTED DISEASESINITIATIVE NORTH AMERICA INC
NTEE Code E05
NTEE Classification Research Institutes and/or Public Policy Analysis
NTEE Type Health - General and Rehabilitative
Classification Charitable Organization
Subsection 501(c)(3)  (View the list of codes)
Activities
Foundation Status Organization which receives a substantial part of its support from a governmental unit or the general public   170(b)(1)(A)(vi)
Deductibility Contributions are deductible
Affiliation Independent - the organization is an independent organization or an independent auxiliary (i.e., not affiliated with a National, Regional, or Geographic grouping of organizations).
Group Name [Not Applicable]
Ruling Date November, 2007
Filing Requirement 990 (all other) or 990EZ return
Fiscal Year End December
IRS Forms 990
(provided courtesy of Foundation Center)
(Log In or Register Now to View Forms 990!)
  • December, 2017
  • December, 2016
  • December, 2015
  • December, 2014
  • December, 2013
Compensation % of Expenses Paid to Title
$169,812 3.69% Rachel Cohen Executive Director
Other Salaries of Note
$178,675 3.88% Jennifer Katz Director of External Affairs

Highly Rated

Charity Name & State Overall Score Overall Rating
Drugs for Neglected Diseases Initiative North America (NY) 82.48 three stars
Tisch MS Research Center of New York (NY) 90.78 four stars
AIDS United (DC) 94.37 four stars
Population Council (NY) 90.03 four stars
Foundation Fighting Blindness (MD) 85.99 three stars

Compare These Charities (Highly Rated)

This charity has an official representative registered with Charity Navigator.

Charity Contact Info

Drugs for Neglected Diseases Initiative North America
40 Wall Street
24th Floor
New York, NY 10005
tel: (646) 616-8680
EIN: 20-8774179

Visit Web Site

Board Leadership

Darin Portnoy
Chair

CEO

Rachel Cohen
Regional Executive Director

Join Our Mailing List

Join over 400,000 other informed givers and get updates on charity ratings, new features, hot topics, and tips for donating.